Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: “Modulating IL-13 Activity Using Mutated IL-13 Molecules that are Antagonists or Agonists of IL-13”, PCT Application PCT/US00/31044 Only written comments and/or license applications that are received by the National Institutes of Health on or before December 30, 2002 will be considered.
View Prospective Grant of Exclusive License: “Nucleic acid encoding mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers” U.S. Patent 6,152,430, Issued November 28, 2000, and “Mesothelium antigen and methods and kits for targeting it” U.S. Patent 6,083,502, Issued July 4, 2000 Only written comments and/or license applications that are received by the National Institutes of Health on or before December 30, 2002 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Drug and Method for the Therapeutic Treatment of Head and Neck Cancer Only written comments and/or license applications which are received by the National Institutes of Health on or before November 25, 2002, will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Co-Exclusive License: Prophylactic and/or Therapeutic Vaccine Against Pseudomonas Aeruginosa Only written comments and/or applications for a license which are received by NIH on or before November 18, 2002 will be considered.
View Prospective Grant of Exclusive License: “Compositions and Methods for In Vitro Fertilization” Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before November 12, 2002, will be considered.
View Prospective Grant of Exclusive License: “Laser Capture Microdissection (LCM) for Cellular Protein Analysis” Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before November 12, 2002, will be considered.
View Prospective Grant of Exclusive License: Human Papilloma Virus-Like Particles for the Induction of Autoantibodies Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before October 28, 2002 will be considered.
View Prospective Grant of Exclusive License: “P2X7 Receptor Antagonists” Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before October 28, 2002 will be considered.
View Prospective Grant of Exclusive License: “Antiprogestins With Partial Agonist Activity Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before October 28, 2002 will be considered.
View Prospective Grant of Exclusive License: Various Retrovirus Isolated From Humans 03/16/99. CDC Reference No. I-012-97/0; New Spumavirus Isolated form Humans, U.S. Patent Application PCT/US98/02598 dated 2/ 12/98. CDC Reference No. I-012-97/1; Spumavirus Isolated from Humans, U.S. Patent Application 09/367,213 dated 12/08/ 1999. CDC Reference No. I-012-97/2; New Retrovirus Isolated from Humans, U.S. Patent Application PCT/US01/51411 dated 10.19.2001. CDC Reference No. I-023-00/0 Spumavirus Isolated from Humans, U.S. Patent Application PCT/US99/25171 dated 10/27/99. CDC Reference No. I-034-97/ 0; Spumavirus Isolated from Humans, U.S. Patent Application Serial No. 09/830,616 filed 9/05/01. CDC Reference No. I-034-97/1;
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant Of Exclusive License: Prophylactic and/or Therapeutic Vaccine Against HCV Infection Only written comments and/or applications for a license which are received by NIH on or before September 24, 2002, will be considered.
View Prospective Grant of Exclusive License: Activity Dependent Neurotrophic Factor (ADNF) III Only written comments and/or license applications which are received by the National Institutes of Health on or before August 16, 2002, will be considered.
View Prospective Grant of Exclusive License: Cytotoxic Treatment of Cancer Cells That Overexpress Matrix Metalloproteinases, Plasminogen Activators and/or Plasminogen Activator Receptors Only written comments and/or license applications that are received by the National Institutes of Health on or before August 16, 2002, will be considered.
View Prospective Grant of Exclusive License: “Compound, Composition and Method For Treating Cancer”, U.S. Patent 6,235,761 Only written comments and/or license applications that are received by the National Institutes of Health on or before August 9, 2002 will be considered.
View Prospective Grant of Exclusive License: “High Throughput Infrared Spectroscopy" Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before September 9, 2002, will be considered.
View Prospective Grant of Exclusive License: Systems and Methods for Aerosol Delivery of Agents 03/15/01.
View Prospective Grant of Exclusive License: Adult Human Dental Pulp Stem Cells In Vitro and In Vivo Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before July 29, 2002 will be considered.
View Opportunity for Cooperative Research and Development Agreement(s) (CRADAs) and/or License(s) for the Development and Commercialization of Nitric Oxide-Releasing Drugs and Biomaterials Confidential CRADA proposal summaries, preferably one page or less, and a signed Confidential Disclosure Agreement (CDA) (http:// ttb.nci.nih.gov/forms.html) must be submitted to the NCI Technology Transfer Branch (TTB) on or before June 24, 2002, to take full advantage of this opportunity. CRADA proposal summaries submitted thereafter may be considered if a suitable CRADA Collaborator is not selected from among the timely responses. Guidelines for preparing a full CRADA proposal will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.
View Prospective Grant of Exclusive License: Treatment of Central Nervous System Disorders With a Combination of Dopaminergic and Adrenergic Antagonists Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 22, 2002, will be considered.
View Prospective Grant of Exclusive License: Adenosine A3 Agonists for Use as Therapeutic Agents Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 22, 2002, will be considered.
View Prospective Grant of Exclusive License: Control of Arthropod Vectors of Parasitic Diseases 06/ 16/00